Credit: Jo Panuwat D/Shutterstock. On November 18, at the American Heart Association (AHA) 100th Annual Meeting 2024, the ...

Long-acting (LA) glucagon-like peptide-1 (GLP-1) receptor agonists (RAs ... Development of antidrug antibodies are common with the LA GLP1-RAs (except for dulaglutide), but there is little ...

The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...

[11] The absence of severe hypoglycemia is consistent with the glucose-dependent insulinotropic mechanism of GLP-1 receptor agonists. The rates of confirmed hypoglycemia were similar between the ...

Structure Therapeutics Inc. (NASDAQ:GPCR) was able to report positive results from its phase 2a study using its GLP-1R agonist GSBR-1290 for the treatment of patients with obesity in June 2024.

Liraglutide was shown to rapidly improve insulin sensitivity as well as decrease blood glucose within two weeks of beginning treatment and before any weight loss. "GLP-1R agonists are an exciting ...

And we had tried small molecules [GLP-1 receptor agonists] too ... because I was very focused on avoiding an antibody response. [Liraglutide has 97% homology with native GLP-1, with just one ...

Lexaria Bioscience (LEXX) has engaged a contract research organization to perform the world’s first-ever fluorescently tagged ...

Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also ...